Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion

BackgroundIn myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differen...

Descripción completa

Detalles Bibliográficos
Autores: Castillo, MI, Ribate, VE, Munoz, CM, Santillana, SG, Taboada, SE, Castera, ME, Abinzano, CMJ, Barranco, IA, Nieto, CR, Pampliega, VM, Blanco, ML, de Andres, AS, de Oteyza, PJ, del Castillo, BT, Font, GI, Cayuela, JA, Diez-Campelo, M, Sanchez, AR, Vercet, SC, Diaz, TM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p17656
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/17656
Access Level:acceso abierto
Palabra clave:20q deletion
myelodysplastic neoplasms
prognosis
quantitative allele-specific PCR
U2AF1 mutations
id ES_dcb3ac39bfbc551a5b5f16b3cf56ce2b
oai_identifier_str oai:incliva.fundanetsuite.com:p17656
network_acronym_str ES
network_name_str España
repository_id_str
spelling Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletionCastillo, MIRibate, VEMunoz, CMSantillana, SGTaboada, SECastera, MEAbinzano, CMJBarranco, IANieto, CRPampliega, VMBlanco, MLde Andres, ASde Oteyza, PJdel Castillo, BTFont, GICayuela, JADiez-Campelo, MSanchez, ARVercet, SCDiaz, TM20q deletionmyelodysplastic neoplasmsprognosisquantitative allele-specific PCRU2AF1 mutationsBackgroundIn myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown. MethodsOur study analyzes different molecular variables in 100 MDS patients with isolated del(20q). Results & ConclusionsWe describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment.WILEY2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/17656Cancer MedicineISSN: 20457634reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p176562026-06-07T16:35:31Z
dc.title.none.fl_str_mv Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
title Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
spellingShingle Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
Castillo, MI
20q deletion
myelodysplastic neoplasms
prognosis
quantitative allele-specific PCR
U2AF1 mutations
title_short Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
title_full Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
title_fullStr Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
title_full_unstemmed Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
title_sort Incidence and prognostic impact of <i>U2AF1</i> mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
dc.creator.none.fl_str_mv Castillo, MI
Ribate, VE
Munoz, CM
Santillana, SG
Taboada, SE
Castera, ME
Abinzano, CMJ
Barranco, IA
Nieto, CR
Pampliega, VM
Blanco, ML
de Andres, AS
de Oteyza, PJ
del Castillo, BT
Font, GI
Cayuela, JA
Diez-Campelo, M
Sanchez, AR
Vercet, SC
Diaz, TM
author Castillo, MI
author_facet Castillo, MI
Ribate, VE
Munoz, CM
Santillana, SG
Taboada, SE
Castera, ME
Abinzano, CMJ
Barranco, IA
Nieto, CR
Pampliega, VM
Blanco, ML
de Andres, AS
de Oteyza, PJ
del Castillo, BT
Font, GI
Cayuela, JA
Diez-Campelo, M
Sanchez, AR
Vercet, SC
Diaz, TM
author_role author
author2 Ribate, VE
Munoz, CM
Santillana, SG
Taboada, SE
Castera, ME
Abinzano, CMJ
Barranco, IA
Nieto, CR
Pampliega, VM
Blanco, ML
de Andres, AS
de Oteyza, PJ
del Castillo, BT
Font, GI
Cayuela, JA
Diez-Campelo, M
Sanchez, AR
Vercet, SC
Diaz, TM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv 20q deletion
myelodysplastic neoplasms
prognosis
quantitative allele-specific PCR
U2AF1 mutations
topic 20q deletion
myelodysplastic neoplasms
prognosis
quantitative allele-specific PCR
U2AF1 mutations
description BackgroundIn myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown. MethodsOur study analyzes different molecular variables in 100 MDS patients with isolated del(20q). Results & ConclusionsWe describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/17656
url https://incliva.portalinvestigacion.com/publicaciones/17656
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv Cancer Medicine
ISSN: 20457634
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421792477577216
score 15.223283

Similares en LA Referencia